Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01743898 · ClinicalTrials.gov registry record
A Prospective Pharmacodynamic Study of Rivaroxaban
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 65
- Enrollment target
NCT01743898: Completed study, sponsored by University of North Carolina, Chapel Hill.
NCT01743898 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 65 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01743898 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 65 participants
- Enrollment target
Study Summary
The ability to explain bleeding or clotting complications in patients treated with rivaroxaban remains challenging. In addition, there is limited data on how coagulation tests perform in patients treated with therapeutic doses of rivaroxaban. Predicted responses of coagulation tests to therapeutic doses of rivaroxaban may be helpful in better understanding abnormal responses to rivaroxaban. The purpose of the study is to define a therapeutic reference range for peak and trough coagulation tests in patients taking FDA approved doses of rivaroxaban and to determine which tests may be most clinically useful for monitoring rivaroxaban.
Interventions
- DRUG Rivaroxaban
- OTHER no anticoagulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2012-10 |
| Est. Completion | 2014-08 |
What the finished NCT01743898 record still lists
NCT01743898 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 65 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Rivaroxaban is the first listed.
NCT01743898 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01743898 about?
NCT01743898 is a clinical study titled "A Prospective Pharmacodynamic Study of Rivaroxaban". The ability to explain bleeding or clotting complications in patients treated with rivaroxaban remains challenging. In addition, there is limited data on how coagulation tests perform in patients treated with therapeutic doses of rivaroxaban. Predicted responses of coagulation tests to therapeutic d...
What is the current status of trial NCT01743898?
This trial is currently completed. The enrollment target is 65 participants. The study started on 2012-10. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01743898?
The interventions under investigation include: Rivaroxaban (DRUG), no anticoagulation (OTHER).
Who is sponsoring clinical trial NCT01743898?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia